LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Начало・Списък с акции・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Затворен

3.92 -1.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.85

Максимум

4.08

Ключови измерители
By Trading Economics
Приходи	5.5M -28M
Продажби	8.2M 13M
EPS	-0.47
Марж на печалбата	-208.694
Служители	172
EBITDA	-1.9M -36M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+219.29% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-18M 237M
Предишно отваряне	5.18
Предишно затваряне	3.92

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

3.17 / 3.4644 Подкрепа & съпротива

Voyager Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.11.2025 г., 21:34 ч. UTC

Печалби

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13.11.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13.11.2025 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13.11.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13.11.2025 г., 23:24 ч. UTC

Печалби

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13.11.2025 г., 23:24 ч. UTC

Печалби

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13.11.2025 г., 23:23 ч. UTC

Печалби

JBS NV 3Q EPS 52c >JBS

13.11.2025 г., 23:23 ч. UTC

Печалби

JBS NV 3Q Sales $22.6B >JBS

13.11.2025 г., 23:04 ч. UTC

Пазарно говорене

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13.11.2025 г., 22:02 ч. UTC

Печалби

Nu Holdings 3Q Net $783M >NU

13.11.2025 г., 22:01 ч. UTC

Печалби

Nu Holdings 3Q Rev $4.2B >NU

13.11.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13.11.2025 г., 21:50 ч. UTC

Печалби

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13.11.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13.11.2025 г., 21:41 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13.11.2025 г., 21:33 ч. UTC

Пазарно говорене

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13.11.2025 г., 21:33 ч. UTC

Печалби

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13.11.2025 г., 21:31 ч. UTC

Печалби

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13.11.2025 г., 21:25 ч. UTC

Печалби

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13.11.2025 г., 21:25 ч. UTC

Печалби

Figure Tech Solutions 3Q EPS 34c >FIGR

13.11.2025 г., 21:23 ч. UTC

Печалби

Intchains Group 3Q Rev $1.3M >ICG

13.11.2025 г., 21:03 ч. UTC

Печалби

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13.11.2025 г., 21:02 ч. UTC

Печалби

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13.11.2025 г., 21:01 ч. UTC

Печалби

Applied Materials 4Q Rev $6.8B >AMAT

13.11.2025 г., 21:01 ч. UTC

Печалби

Applied Materials 4Q Gross Margin 48.0% >AMAT

Сравнение с други в отрасъла

Ценова промяна

Voyager Therapeutics Inc Прогноза

Ценова цел

By TipRanks

219.29% нагоре

12-месечна прогноза

Среден 13.57 USD 219.29%

Висок 25 USD

Нисък 8 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Voyager Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Voyager Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.17 / 3.4644Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.